Filter
1780
Text search:
vaccine
supply
Featured
221
469
Language
Document type
751
360
275
140
96
75
39
24
13
2
2
2
1
Countries / Regions
98
91
50
48
47
46
42
37
33
31
30
28
27
25
25
24
24
22
22
20
20
19
18
17
16
15
15
13
13
13
13
12
12
11
11
11
10
10
9
9
9
9
7
7
7
6
6
5
5
4
4
4
4
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
763
133
93
88
80
24
14
1
Toolboxes
371
78
71
59
50
48
46
45
45
41
38
34
33
32
31
29
28
27
26
10
10
8
6
6
1
1
The Kenyan Health Sector has been playing a critical role in
providing health care services in response to the population
needs in line with the Kenya Health Policy, 2014-2030’s goal
of attaining the highest possible health standards in a manner
responsive to the population needs.
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence s
...
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat
...
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and a
...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the back
...
This policy brief draws from the latest evidence on the impact of vaccination program start date and vaccine rollout rates on health benefits. The objective is to support policymakers on decisions to procure COVID-19 vaccines and roll out vaccinatio
...
first issued 18 August 2022
Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in ch
...
This resource offers practical guidance in managing the supply chain, with emphasis on health comodities. The handbook is particularly useful for program managers who design, manage, and assess logistics system for health program. The document inclu
...
Interim Guidance, 12 July 2021; This tool was developed to assess present and surge capacities for the treatment of COVID-19 in health facilities. It allows health facilities to assess the availability and status of stockout of critical COVID-19 medicines, equipment and supplies on site and to ident
...
The conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of pla
...
This quick guide offers basic information about COVID-19, the Sinovac-CoronaVac COVID-19 vaccine and what to
expect following vaccination: ...
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary include
...
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
